THERACLION announces presentation of U.S. clinical data supporting Echotherapy with Echopulse® for breast fibroadenomas at The American Society of Breast Surgeons (ASBrS) Annual Meeting
Echotherapy was well-tolerated and resulted in minimal side effects.
Results suggest positive outcome of the ongoing pivotal trial of Echopulse® for non-invasive treatment of breast fibroadenomas.
THERACLION today announced the presentation of data from the U.S. feasibility trial of echotherapy with Echopulse®, a non-invasive treatment employing ultrasound-guided high-intensity focused ultrasound (HIFU), in women with breast fibroadenomas. Results were presented at The American Society of Breast Surgeons (ASBrS) Annual Meeting, held April 26 – 30 in Las Vegas, NV.